Full Text
PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU- A PERSPECTIVE FROM REGULATORS AND PAYERS

Abstract

Authors

A.F. Fonseca S.N. Deplazes

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×